Fig. 2
From: JNK signaling provides a novel therapeutic target for Rett syndrome
D-JNKI1 rescues well-being conditions, locomotor impairments, and apnea numbers in Mecp2y/- male mice. a Timeline of D-JNKI1 treatment in Mecp2y/- male mice. b Growth curves of D-JNKI1-treated (blue sky) and untreated (black) wild type, and D-JNKI1-treated (fuchsia) and untreated (black-dotted) Mecp2y/- mice from 3 to 7 weeks of age (n=25 for each experimental group). c, d Behavioral analysis of D-JNKI1-treated vs untreated wt and Mecp2y/- mice (n=10 for each experimental group) from 3 to 7 weeks of age in the Rotarod (c) and open field (d) tests (parameters shown: time spent immobile and distance moved, with relative open field arena-plots). e Western blots and the quantification P-c-Jun/c-Jun ratio in the whole homogenate of the cortex, hippocampus, and cerebellum of 7-week-old D-JNKI1-treated and untreated Mecp2y/- mice. f Timeline of D-JNKI1 treatment and plethysmography analysis. g Number and duration of apnea in preventive and curative D-JNKI1 paradigm of treated (n=10) and untreated (n=6) wild type and Mecp2y/- mice (n=15) from 6 to 9 weeks of age. h Breathing analysis in preventive (lower part) and curative (upper part) D-JNKI1 paradigm of treated (fuchsia) and untreated Mecp2y/- (white) mice from 6 to 9 weeks of age and the treated (blue-sky) and untreated wild type (black) (parameters shown: Ti, Te, and f). Data were shown as mean ± SEM. Significance was calculated using two‐way ANOVA for repetitive measurements followed by Bonferroni post hoc test (panels a, b, c, e, f) or Student’s t test followed by Tukey’s post hoc test (panels d). Statistical significance relative to control **p<0.01, ***p<0.001, and ****p<0.0001; D-JNKI1-treated vs untreated Mecp2y/-: #p<0.05, ##p<0.01, ####p<0.0001